PL3484889T3 - Pochodne etynylu - Google Patents

Pochodne etynylu

Info

Publication number
PL3484889T3
PL3484889T3 PL17742971T PL17742971T PL3484889T3 PL 3484889 T3 PL3484889 T3 PL 3484889T3 PL 17742971 T PL17742971 T PL 17742971T PL 17742971 T PL17742971 T PL 17742971T PL 3484889 T3 PL3484889 T3 PL 3484889T3
Authority
PL
Poland
Prior art keywords
ethynyl derivatives
ethynyl
derivatives
Prior art date
Application number
PL17742971T
Other languages
English (en)
Inventor
Barbara BIEMANS
Georg Jaeschke
Antonio Ricci
Daniel Rueher
Fionn O`HARA
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL3484889T3 publication Critical patent/PL3484889T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL17742971T 2016-07-18 2017-07-12 Pochodne etynylu PL3484889T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16179837 2016-07-18
EP17742971.9A EP3484889B1 (en) 2016-07-18 2017-07-12 Ethynyl derivatives
PCT/EP2017/067495 WO2018015235A1 (en) 2016-07-18 2017-07-12 Ethynyl derivatives

Publications (1)

Publication Number Publication Date
PL3484889T3 true PL3484889T3 (pl) 2020-12-28

Family

ID=56418435

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17742971T PL3484889T3 (pl) 2016-07-18 2017-07-12 Pochodne etynylu

Country Status (31)

Country Link
US (3) US20190144458A1 (pl)
EP (1) EP3484889B1 (pl)
JP (1) JP6936305B2 (pl)
KR (1) KR20190026805A (pl)
CN (1) CN109476671B (pl)
AR (1) AR109075A1 (pl)
AU (1) AU2017299083B2 (pl)
BR (1) BR112019000314A2 (pl)
CA (1) CA3030788A1 (pl)
CL (1) CL2019000045A1 (pl)
CO (1) CO2018013824A2 (pl)
CR (1) CR20190014A (pl)
DK (1) DK3484889T3 (pl)
ES (1) ES2826389T3 (pl)
HR (1) HRP20201615T1 (pl)
HU (1) HUE051006T2 (pl)
IL (1) IL263884A (pl)
LT (1) LT3484889T (pl)
MA (1) MA45665B1 (pl)
MX (1) MX376249B (pl)
PE (1) PE20190382A1 (pl)
PH (1) PH12019500119A1 (pl)
PL (1) PL3484889T3 (pl)
PT (1) PT3484889T (pl)
RS (1) RS60908B1 (pl)
RU (1) RU2745068C2 (pl)
SG (1) SG11201811829QA (pl)
SI (1) SI3484889T1 (pl)
TW (1) TWI729169B (pl)
WO (1) WO2018015235A1 (pl)
ZA (1) ZA201900113B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA120463C2 (uk) 2015-07-15 2019-12-10 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як модулятори метаботропного рецептора глутамату
CN110183456A (zh) * 2019-07-11 2019-08-30 河南师范大学 一种2-芳基吲唑琥珀酰亚胺螺环化合物的合成方法
US11515154B2 (en) * 2020-10-27 2022-11-29 Applied Materials, Inc. Selective deposition of a passivation film

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2508581A1 (en) * 2002-12-04 2004-06-17 Merck & Co., Inc. Spirocyclic ureas, compositions containing such compounds and methods of use
PL1891075T3 (pl) 2005-05-24 2011-12-30 Merck Serono Sa Spiropochodne tricykliczne jako modulatory CRTH2
WO2008027466A1 (en) 2006-08-31 2008-03-06 Schering Corporation Hydantoin derivatives useful as antibacterial agents
KR20100033981A (ko) 2007-06-03 2010-03-31 벤더르빌트 유니버시티 벤즈아미드 대사성 글루타민산염 수용체5 양성 알로스테릭 조절자 및 이의 제조 및 사용방법
RU2012114770A (ru) 2009-09-04 2013-10-10 Вандербилт Юниверсити АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ
US8389536B2 (en) 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
US8759377B2 (en) 2009-11-23 2014-06-24 Vanderbilt University Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
US8772300B2 (en) 2011-04-19 2014-07-08 Hoffmann-La Roche Inc. Phenyl or pyridinyl-ethynyl derivatives
HRP20150555T1 (hr) 2011-04-26 2015-07-03 F. Hoffmann - La Roche Ag Derivati etinila kao pozitivni alosterijski modulatori za mglur5
EP2702050B1 (en) 2011-04-26 2016-05-18 F.Hoffmann-La Roche Ag Pyrazolidin-3-one derivatives
WO2012162635A1 (en) 2011-05-26 2012-11-29 Sunovion Pharmaceuticals Inc. Metabotropic glutamate receptors 5 modulators and methods of use thereof
AU2012278976B2 (en) * 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
US20130123254A1 (en) 2011-09-30 2013-05-16 Barbara Biemans Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification
UA110862C2 (uk) 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5
UA110995C2 (uk) 2011-10-07 2016-03-10 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як модулятори метаботропного глутаматного рецептора
AU2013292142B2 (en) 2012-07-17 2017-03-09 F. Hoffmann-La Roche Ag Arylethynyl derivatives
MY171517A (en) 2012-10-18 2019-10-16 Hoffmann La Roche Ethynyl derivatives as modulators of mglur5 receptor activity
CN104718191B (zh) 2012-10-18 2016-06-29 霍夫曼-拉罗奇有限公司 作为mglur5受体活性调节剂的乙炔基衍生物
WO2014124560A1 (en) 2013-02-18 2014-08-21 Hua Medicine (Shanghai) Ltd. Mglur regulators
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
EA029352B1 (ru) 2013-09-25 2018-03-30 Ф. Хоффманн-Ля Рош Аг Производные этинила
TWI649310B (zh) 2014-01-10 2019-02-01 赫孚孟拉羅股份公司 乙炔基衍生物
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
HUE041392T2 (hu) 2014-02-25 2019-05-28 Hoffmann La Roche Etinil származékok
CN107207481B (zh) 2015-03-19 2020-03-03 豪夫迈·罗氏有限公司 作为mglur4的调节剂的3-(4-乙炔基苯基)六氢嘧啶-2,4-二酮衍生物
UA120463C2 (uk) * 2015-07-15 2019-12-10 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як модулятори метаботропного рецептора глутамату
US10391998B2 (en) 2016-11-16 2019-08-27 Ford Global Technologies, Llc Vehicle systems and methods for reducing electrified vehicle noise, vibration, and harshness

Also Published As

Publication number Publication date
CO2018013824A2 (es) 2018-12-28
PE20190382A1 (es) 2019-03-08
US11242349B2 (en) 2022-02-08
ES2826389T3 (es) 2021-05-18
MA45665B1 (fr) 2020-11-30
RU2745068C2 (ru) 2021-03-18
SI3484889T1 (sl) 2020-11-30
SG11201811829QA (en) 2019-02-27
JP6936305B2 (ja) 2021-09-15
JP2019521158A (ja) 2019-07-25
US20200255440A1 (en) 2020-08-13
LT3484889T (lt) 2020-11-10
TW201805287A (zh) 2018-02-16
RU2019102757A3 (pl) 2020-08-18
TWI729169B (zh) 2021-06-01
HUE051006T2 (hu) 2021-01-28
ZA201900113B (en) 2019-09-25
BR112019000314A2 (pt) 2019-04-16
US20220127275A1 (en) 2022-04-28
EP3484889A1 (en) 2019-05-22
CN109476671A (zh) 2019-03-15
HRP20201615T1 (hr) 2020-12-11
RS60908B1 (sr) 2020-11-30
CA3030788A1 (en) 2018-01-25
MX376249B (es) 2025-03-07
CN109476671B (zh) 2021-09-24
US12145940B2 (en) 2024-11-19
PH12019500119A1 (en) 2019-12-11
RU2019102757A (ru) 2020-08-18
AU2017299083B2 (en) 2021-06-24
AU2017299083A1 (en) 2019-01-24
PT3484889T (pt) 2020-10-15
DK3484889T3 (da) 2020-10-26
CL2019000045A1 (es) 2019-06-07
EP3484889B1 (en) 2020-08-19
KR20190026805A (ko) 2019-03-13
US20190144458A1 (en) 2019-05-16
MX2019000442A (es) 2019-06-20
IL263884A (en) 2019-01-31
AR109075A1 (es) 2018-10-24
WO2018015235A1 (en) 2018-01-25
CR20190014A (es) 2019-03-04

Similar Documents

Publication Publication Date Title
ZA201800826B (en) Substituted oxopyridine derivatives
IL253381A0 (en) History of h9-pyrrolo-dipyridine
IL254473A0 (en) Derivatives of morphinan
SG11201609205WA (en) Heterocyclyl-butanamide derivatives
PL3164393T3 (pl) Pochodne flawaglin
HUE050450T2 (hu) Fluoralkil-fluorén-származékok
IL248773A0 (en) History of naphthyridinedione
IL251005B (en) Pyrido-oxazinone derivatives
ZA201605243B (en) Ethynyl derivatives
IL255103A0 (en) Ethinyl history
AP2016009530A0 (en) Cycloalkyl-linked diheterocycle derivatives
PL3119744T3 (pl) Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
ZA201900113B (en) Ethynyl derivatives
GB201414116D0 (en) Benzodiazepine derivatives
PL3228616T3 (pl) Pochodne pirydyny
ZA201802194B (en) Aminoazole derivative
IL255367B (en) Ethinyl history
PT3319956T (pt) Derivados de oxopiridina substituída